Who are Upstream Bio's investors?

Upstream Bio's investors include Access Biotechnology, Bain Capital Life Sciences, Decheng Capital, OrbiMed, TCG Crossover.

Upstream Bio

NASDAQ: UPB

Founded 2021 · Incorporated in Delaware · 5 known investors

upstreambio.com ↗

Upstream Bio is a clinical-stage biotechnology company developing verekitug, an antagonist that targets the TSLP receptor to inhibit pro-inflammatory signaling. Its clinical trials evaluate the treatment of chronic inflammatory respiratory diseases including severe asthma, CRSwNP, and COPD.

BiotechHealthtech

Founders & leadership

Rand Sutherlandin

Investors · 5

Access BiotechnologyNew York City

Bain Capital Life SciencesBoston

Decheng CapitalMenlo Park

OrbiMedNew York · $1M – $75M

TCG CrossoverPalo Alto

In the news

Upstream Bio (NASDAQ: UPB) reports Q2 2026 loss and advances Phase 3 plansstocktitan.net · Aug 2026

Upstream Bio posts $80M loss, holds $261M cash | UPB Quarterly Report (10-Q)stocktitan.net · Aug 2026

Upstream Bio, two other U.S. biotech startups price IPOs as healthcare listings rise | Reutersreuters.com · Oct 2024

Frequently asked questions

What does Upstream Bio do?: Upstream Bio is a clinical-stage biotechnology company developing verekitug, an antagonist that targets the TSLP receptor to inhibit pro-inflammatory signaling. Its clinical trials evaluate the treatment of chronic inflammatory respiratory diseases including severe asthma, CRSwNP, and COPD.
Who are Upstream Bio's investors?: Upstream Bio's investors include Access Biotechnology, Bain Capital Life Sciences, Decheng Capital, OrbiMed, TCG Crossover.